## STROBE Statement—checklist of items that should be included in reports of observational studies

| Section/item | Item No | Recommendation | Reported on Page Number/Line Number | Reported on Section/Paragraph |
|---|---|---|---|---|
| **Title and abstract** | 1 | (a) Indicate the study's design with a commonly used term in the title or the abstract | Page 3 Lines 58-60 | Abstract |
| | | (b) Provide in the abstract an informative and balanced summary of what was done and what was found | Page 3-4 Lines 61- 79 | Abstract |
| **Introduction** | | | | |
| Background/ rationale | 2 | Explain the scientific background and rationale for the investigation being reported | Page 5 Lines 87-103 | 1 Introduction |
| Objectives | 3 | State specific objectives, including any prespecified hypotheses | Page 6 Lines 104-106 | 1 Introduction |
| **Methods** | | | | |
| Study design | 4 | Present key elements of study design early in the paper | Page 6 Lines 112-119 | 2 Methods/ 2.1 Patients |
| Setting | 5 | Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection | Pages 6-7 Lines 112 -134 | 2 Methods/ 2.1 Patients |
| Participants | 6 | (a) ***Cohort study***—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up<br>***Case-control study***—Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls<br>***Cross-sectional study***—Give the eligibility criteria, and the sources and methods of selection of participants | Page 6 Lines 112-119<br>Pages 8-9 Lines 166-169 | 2 Methods/ 2.1 Patients<br><br>2 Methods/ 2.3 Lesion dosimetry |
| | | (b) ***Cohort study***—For matched studies, give matching criteria and number of exposed and unexposed<br>***Case-control study***—For matched studies, give matching criteria and the number of controls per case | N/A In this study all the patients underwent to the | N/A |
| Variables | 7 | Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable | Pages 6-7 Lines 128-134 | 2 Methods/2.1 Patients |
| Data sources/ measurement | 8* | For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group | Pages 7-9 Lines 136-206 | 2 Methods/2.2 WB/RM Dosimetry |
| Bias | 9 | Describe any efforts to address potential sources of bias | Page 8-9 Lines 166-169 | 2 Methods/2.3 Lesion |
| Study size | 10 | Explain how the study size was arrived at | Page 6 Lines 112-115 | 2 Methods /2.1 Patients |
| Quantitative variables | 11 | Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why | Pages 7-9 Lines 136-206 | 2 Methods/2.2 WB/RM Dosimetry |

| | | | | |
|---|---|---|---|---|
| Statistical methods | 12 | (a) Describe all statistical methods, including those used to control for confounding | Page 10 Lines 201-206 | 2 Methods /2.4 Statistical |
| | | (b) Describe any methods used to examine subgroups and interactions | Page 10 Lines 201-206 | 2 Methods /2.4 Statistical |
| | | (c) Explain how missing data were addressed | N/A In this study all | N/A |
| | | (d) ***Cohort study***—If applicable, explain how loss to follow-up was addressed<br>***Case-control study***—If applicable, explain how matching of cases and controls was addressed<br>***Cross-sectional study***—If applicable, describe analytical methods taking account of sampling strategy | N/A these recomendations are not appllicable in a case series study | N/A |
| | | (e) Describe any sensitivity analyses | N/A The sensitivity | N/A |
| **Results** | | | | |
| Participants | 13* | (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed | Pages 10-11 Lines 213-219 | 3 Results/3.1 Clinical results |
| | | (b) Give reasons for non-participation at each stage | N/A All patients | N/A |
| | | (c) Consider use of a flow diagram | N/A The authors decide to | N/A |
| Descriptive data | 14* | (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders | Pages 10-11 Lines 214-216 | 3 Results/3.1 Clinical results |
| | | (b) Indicate number of participants with missing data for each variable of interest | N/A the patient dataset | N/A |
| | | (c) ***Cohort study***—Summarise follow-up time (eg, average and total amount) | Pages 11 Lines 215-219 | 3 Results/3.1 Clinical |
| Outcome data | 15* | ***Cohort study***—Report numbers of outcome events or summary measures over time | Pages 11 Lines 215-219 | 3 Results/3.1 Clinical |
| | | ***Case-control study***—Report numbers in each exposure category, or summary measures of exposure | N/A This study is a | N/A |
| | | ***Cross-sectional study***—Report numbers of outcome events or summary measures | N/A This study is a | N/A |
| Main results | 16 | (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included | N/A Unadjusted estimates and confounder-adjusted | N/A |
| | | (b) Report category boundaries when continuous variables were categorized | Pages 11-13 Lines | 3 Results/3.2Absorbed |
| | | (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period | N/A Not relevant | N/A |
| Other analyses | 17 | Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses | Page 13 Lines 264-267 | 3 Results/3.3Absorbed |
| **Discussion** | | | | |
| Key results | 18 | Summarise key results with reference to study objectives | Page 13 Lines 270-275 | 4 Discussion |
| Limitations | 19 | Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias | Page 16 Lines 339 -348 | 4 Discussion |

| | | | | |
|---|---|---|---|---|
| Interpretation | 20 | Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence | Pages 13-15 Lines 276-334 | 4 Discussion |
| Generalisability | 21 | Discuss the generalisability (external validity) of the study results | Pages 16-17 Lines | 4 Discussion |
| **Other information** | | | | |
| Funding | 22 | Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based | Page 18 Line 412 | Fundings |

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.

Article information: https://dx.doi.org/10.21037/qims-21-548
*As the checklist was provided upon initial submission, the page number/line number reported may be changed due to copyediting and may not be referable in the published version. In this case, the section/paragraph may be used as an alternative reference.